Optical Waveguide EV Biosensing in High-Throughput Microplates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and analyzing extracellular vesicles (EVs) are cumbersome, require specialized equipment, can damage EVs, lead to contamination, or have low throughput, and are not easily adaptable to microplate formats.
Innovation Solution
An optical biosensor system using optical waveguide biosensors integrated into a microplate format that allows for the isolation, purification, and analysis of EVs through binding agents specific to EV surface markers, enabling high-throughput phenotyping and quantification without labels, and allowing for intravesicular content analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods such as ultracentrifugation are used to isolate EVs, then EVs can be separated from sample medium, but specialized equipment is required and EVs are subjected to extreme forces that can damage them
Solution Approach 1:
The patent replaces mechanical isolation methods (ultracentrifugation, filtration) with optical detection methods. EVs are detected directly in the sample medium using optical biosensors that measure light scattering or refractive index changes, eliminating the need for mechanical separation equipment and extreme forces that damage EVs
Solution Approach 2:
The patent introduces binding agents (antibodies, aptamers) as intermediaries that specifically bind to EV surface markers. These binding agents attach EVs to magnetic beads or sensor surfaces, enabling selective isolation and detection without mechanical stress, thus preserving EV integrity while simplifying equipment requirements
2Reliability
If ultrafiltration methods are used to isolate EVs, then EVs can be separated from sample medium, but EV loss occurs due to non-specific binding to membrane materials
Solution Approach 1:
The patent replaces membrane filtration with optical detection methods that require no physical contact between EVs and membrane surfaces, completely eliminating non-specific binding losses. EVs are detected in suspension or after gentle binding to functionalized surfaces, preserving recovery rates
Solution Approach 2:
The patent uses specifically engineered binding agents with high affinity and specificity for EV markers. These intermediaries selectively capture target EVs from complex samples without the non-specific adsorption that occurs with membrane materials, significantly improving EV recovery
3Reliability
If precipitation methods are used to isolate EVs, then EVs can be concentrated from sample medium, but results are contaminated with proteins or other molecules
Solution Approach 1:
The patent employs highly specific binding agents (monoclonal antibodies, aptamers) that selectively bind to unique EV surface markers. This specific recognition enables clean separation of EVs from contaminating proteins and molecules, achieving high purity without the contamination inherent in precipitation methods
Solution Approach 2:
The patent applies binding agents with specific affinity for EV markers at the molecular level, creating selective binding zones that distinguish EVs from other sample components. This localized specificity enables precise isolation of pure EV populations while maintaining rapid processing speeds
4Reliability
If chromatography columns are used to separate EVs, then EVs can be purified based on affinity, size exclusion, or ion exchange, but the process is laborious and time-consuming
Solution Approach 1:
The patent replaces complex chromatography systems with simplified magnetic separation or direct optical detection. EVs bound to magnetic beads are separated by simple magnetic attraction, or EVs are detected directly in suspension using optical sensors, reducing purification time from hours to minutes while maintaining high purity
Solution Approach 2:
The patent uses binding agents coupled to magnetic beads as intermediaries. These conjugates selectively capture EVs from samples, and the bound EVs are rapidly separated by magnetic field application. This approach achieves chromatography-level purity in a fraction of the time, eliminating laborious column operations
5Quantity of substance
If microfluidic devices are used to analyze EVs, then analysis can be performed with small sample volumes, but throughput is very low
Solution Approach 1:
The patent develops optical biosensor platforms that can simultaneously analyze multiple samples in parallel (e.g., 96-well plate format). Each well functions as an independent detection channel, enabling high-throughput analysis of many samples with minimal sample volume, achieving both sensitivity and productivity
Solution Approach 2:
The patent divides the analysis into discrete, parallel detection channels using multi-well plate formats. Each well contains binding agents specific to different EV markers or sample types, allowing simultaneous multiplexed analysis of multiple samples or multiple EV subpopulations, dramatically increasing throughput while maintaining low sample volume requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables efficient, high-throughput isolation, purification, and analysis of EVs directly from complex samples, reducing damage and contamination, and facilitating phenotyping and intravesicular content analysis in a single step.
Implementation Method 1
an optical reader configured to receive and analyze a microplate having a number of wells where each well includes an optical waveguide biosensor
Data Source
AI summary
Various implementations of a system and method for analyzing extracellular vesicles (EVs) are disclosed having a number of innovative features. In one implementation, a method for analyzing EVs includes binding EVs to an optical waveguide biosensor and phenotyping the bound EVs. Phenotyping can include binding a labeled ligand to the EVs and/or rupturing the EVs and analyzing their cargo. In another implementation, a system for analyzing EVs includes EVs bound to an optical waveguide biosensor and a labeled ligand bound to the EVs. In another implementation, a kit for analyzing EVs includes a micro plate having wells containing optical waveguide biosensors functionalized with a binding agent configured to bind to EVs and at least one of: (a) labeled ligands configured to bind to the extracellular vesicles or (b) a reagent configured to rupture the extracellular vesicles.